Legend Biotech Corp
LEGN Nasdaq· Pharmaceutical Preparations
Last close · Nov 9, 2026
$24.29
Latest quarter · Q4 '25 results quarter ended Dec 31, 2025 · vs Q4 '24
| Line | Q4 '24 | Q4 '25 | Change (y/y) |
|---|---|---|---|
| Revenue | $187M | $306M | 64.3% |
| Net income | $26.3M | −$30.8M | 217.2% |
| Diluted EPS | $0.14 | −$0.18 | 228.6% |
| Operating margin | −42.5% | −6.4% | 36.1 pts |
| Free cash flow | −$84.4M | −$24.6M | — |
Key numbers, fiscal 2025
Market cap
$4.5B
P/E
—
Revenue
$1.0B
Net income
−$297M
Free cash flow
−$129M
Operating margin
−13.3%
Legend Biotech Corp in 30 seconds fiscal 2025
Are sales growing?
+64.0%
Yes. Sales grew 64.0% last year.
Does it make a profit?
−28.8%
No. It lost money last year.
How long would its cash last?
7.0 yrs
Comfortably. It burns $129M a year and holds $902M, about 7.0 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Legend Biotech Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 10, 2026
- Legal name
- Legend Biotech Corp
- CIK
- 0001801198
Legend Biotech Corp · LEGN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $68.8M | $117M | $285M | $627M | $1.0B |
| Revenue growth | −8.2% | 70.0% | 143.7% | 120.0% | 64.0% |
| Gross margin | 100.0% | 44.1% | 49.4% | 65.5% | 61.4% |
| Operating margin | — | — | −185.2% | −49.3% | −13.3% |
| Net income | −$404M | −$446M | −$518M | −$177M | −$297M |
| Net margin | −586.4% | −381.5% | −181.8% | −28.2% | −28.8% |
| Diluted EPS | −$2.86 | −$2.80 | −$2.94 | −$0.96 | −$1.62 |
| Cash | |||||
| Cash from operations | −$198M | −$201M | −$393M | −$144M | −$100M |
| Capital expenditure | $42.2M | $20.9M | $20.1M | $14.1M | $28.6M |
| Free cash flow | −$241M | −$222M | −$413M | −$158M | −$129M |
| FCF margin | −349.7% | −189.9% | −145.0% | −25.2% | −12.5% |
| Share count change | 19.2% | 12.9% | 10.7% | 3.8% | 0.8% |
| Debt and strength | |||||
| Cash and short-term investments | $689M | $786M | $1.3B | $287M | $902M |
| Debt incl. finance leases | $120M | $250M | $250M | $250M | $319M |
| Shareholders' equity | $766M | $744M | $1.3B | $1.0B | $1.0B |
| Current ratio | 4.1x | 3.7x | 6.9x | 4.6x | 2.0x |
| Interest coverage | — | — | −24.2x | −14.3x | −6.4x |
| Returns and quality | |||||
| Return on capital | — | — | −186.5% | −24.4% | −25.7% |
| Return on equity | −59.2% | −59.1% | −51.9% | −15.4% | −29.1% |
| Return on tangible equity | −53.0% | −60.2% | −41.5% | −17.0% | −29.7% |
| Piotroski F-score | 2 | 3 | 6 | 4 | 2 |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.6M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Legend Biotech Corp · LEGN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001801198). Latest version: stoqly.net/companies/legn. Data updated November 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.